Navigation Links
New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
Date:11/30/2011

A 200 mg dose of Vimpat® oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Common Adverse Reactions

The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat®-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment.  The use of Vimpat® in patients with severe hepatic impairment is not recommended. 

For full prescribing information on Vimpat®, visit http://www.vimpat.com/prescribing-information.aspx. (Accessed 18 October, 2011)

For more information on Vimpat®, visit www.Vimpat.com or contact UCB at 800.477.7877.

Vimpat® (C-V) is a Schedule V controlled substance.
Vimpat® is a registered trademark used under license from Harris FRC Corporation.

Important safety information about Vimpat® in the EU and EEA
Vimpat® is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. Lacosamide solution for infusion is an alternative for patients when oral administration is temporarily not feasible. Contraindications: Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with lacosamide have been observed in clinical st
'/>"/>

SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V
2. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
3. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
4. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
5. Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011
6. Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
7. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
9. LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
10. Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting
11. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2012  Biomerix Corporation announced today that it has received ... tissue repair mesh, a novel composite mesh intended for ... for the temporary bridging of fascial defects.  This approval ... certification in many other parts of the world that ...
... 2012  Sanofi US today announced that the U. S. ... injunction against a Synvisc-One ® (hylan ... ruling allows for a restricted launch of Seikagaku,s product ... prohibits Seikagaku from selling their product below the current ...
Cached Medicine Technology:Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh 2Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product 2
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based ... its new True North Conference Center. The medical community, social workers, law enforcement, ... may be more aligned in the effort to better understand and combat sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Radiation Oncology (ASTRO) has released evidence-based guidelines to ... finding that hypofractionated (HF) WBI is effective for ... are published in the International Journal of ... , Studies have shown that WBI following breast ...
... that controls the number of hematopoietic stem cells cells ... In a report in the online Early Edition of ... from Massachusetts General Hospital (MGH) and the Harvard Stem Cell ... of these blood stem cells, an advance that may improve ...
... By Jenifer Goodwin HealthDay Reporter , ... outbreak of whooping cough in decades, public health officials ... those who come into contact with infants, to make ... With the incidence of whooping cough also higher than ...
... DC Delivering timely, open, online access to the ... will significantly increase the return on the public,s investment ... Houghton at the Centre for Strategic Economic Studies at ... on Investment in Open Archiving Publicly Funded Research Outputs," ...
... Yeni H. Ycel, an ophthalmic pathologist at St. Michael,s Hospital, ... the New York Academy of Medicine. Dr. Ycel received ... the human eye that may lead to new treatments for ... assumption that the eye has no lymphatics, the channels responsible ...
... accurately detect and alleviate symptoms of delirium in persons ... the National Institute of Nursing Research. The project, ... seeks to improve nurses, assessment skills and reduce the ... Delirium and dementia have similar symptoms -- decline in ...
Cached Medicine News:Health News:ASTRO publishes whole breast irradiation guidelines 2Health News:MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment 2Health News:Spread of Whooping Cough Raises Concern 2Health News:Spread of Whooping Cough Raises Concern 3Health News:New study examines the economic returns of public access policies 2Health News:Nurses will test method for determining if it's dementia or delirium 2
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: